This scenario has to be revised in cases of rGBM carrying an IDH mutation (IDH1 MUTANT astrocytoma according to 2021 WHO classification [28]), which is defined as a driver in gliomas, owing to the critical role of IDH in influencing the functional state of GAMs [29,30,31]. This evidence concerns the gene IDH1 and central nervous system cancer.